医薬品開発・製造受託機関の2030年までの市場予測： サービスタイプ別、分子タイプ別、剤形別、用途別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の医薬品開発・製造受託機関市場は2024年に2,432億9,000万米ドルを占め、2030年には3,546億8,000万米ドルに達し、CAGR 8.4%となると予測されています。

医薬品開発・製造受託機関（CDMO）は、製薬会社やバイオテクノロジー企業に包括的なサービスを提供する専門企業です。これらのサービスは、最初の製品コンセプトから商業生産に至るまで、医薬品の開発・製造プロセス全体を網羅しています。CDMOは、製剤開発、分析試験、プロセス最適化、法規制遵守などの専門知識を記載しています。CDMOは、医薬品開発・製造の様々な側面をアウトソーシングすることで、顧客はCDMOの専門的能力とインフラの恩恵を受けながら、コアコンピタンスに集中することができます。

国家衛生委員会（NHC）によると、中国には慢性疾患に苦しむ高齢者が1億8,000万人以上おり、そのうち75％が複数の慢性疾患に罹患しています。

成長するバイオ医薬品市場

バイオ医薬品市場の拡大は、専門的な専門知識とインフラに対する需要を煽り、PCDMOの拡大を促進しています。このような組織は、医薬品開発、製造、試験のためのオーダーメイドのソリューションを提供し、バイオ医薬品特有の要件に対応しています。CDMOは製薬会社のプロセスを合理化し、コストを削減し、リスクを軽減することで、イノベーションを促進し、新治療法の市場投入までの時間を短縮します。バイオ医薬品が市場開拓の主役であり続ける中、CDMOは開発・商業化の支援において極めて重要な役割を果たしており、このセグメントの成長軌道に拍車をかけています。

厳しい規制要件とコンプライアンス基準

CDMOにおける厳しい規制要件とコンプライアンス基準は、製品の品質、安全性、有効性を確保するために不可欠です。これらの基準は、運営コストの増加、市場開拓期間の長期化、中小企業にとっての参入障壁の形成により、市場成長の妨げとなる可能性があります。コンプライアンスへの取り組みには多大なリソースが必要となることが多く、サービスや製品の価格上昇につながります。さらに、厳しい規制は技術革新を抑制し、市場の需要に適応する柔軟性を制限するため、市場全体の拡大と競合を阻害する可能性があります。

専門知識への需要の高まり

製薬企業が外部の専門知識を活用しながらコアコンピタンスに集中しようとする中、CDMOは製剤開発、製造、包装などの専門サービスを提供する上で重要な役割を果たしています。この動向は、最新の医薬品開発の複雑さ、厳しい規制要件、費用対効果の高い戦略の必要性によって促進されています。CDMOは、製剤開発、分析試験、製造、包装を含む幅広いサービスを提供し、製薬会社が製品パイプラインを加速し、革新的な治療を効率的に市場に投入することを可能にし、市場拡大を後押ししています。

価格圧力

CDMOにおける価格圧力は、競争の激化、規制の変更、原材料や人件費の高騰によって生じる。こうした圧力はしばしば価格下落傾向につながり、利益率を圧迫し、技術革新や事業拡大への投資を妨げます。その結果、CDMOは収益性を維持するのに苦労し、先端技術やインフラのアップグレードに投資できなくなる可能性があります。このような投資抑制のサイクルは、新薬の開発を妨げ、業界が進化する医療ニーズに対応する能力を制限する可能性があります。

COVID-19の影響

COVID-19の流行は、医薬品開発・製造受託機関市場に様々な影響を与えました。ワクチンや治療など特定の医薬品に対する需要が急増し、製造支援のためにCDMOへのアウトソーシングが増加した一方で、パンデミックはサプライチェーンを混乱させ、臨床試験や規制プロセスを遅らせた。全体として、パンデミックは機敏で回復力のある製造能力の重要性を強調し、将来の混乱を緩和するための技術とインフラへの投資を促進しました。

予測期間中、開発サービスセグメントが最大となる見込み

開発サービスセグメントは有利な成長を遂げると推定されます。開発サービスの医薬品開発・製造受託機関は、創薬から臨床試験まで包括的なサポートを記載しています。これらのサービスには、製剤開発、分析法開発、安定性試験、薬事申請などが含まれます。CDMOは、製薬会社が開発期間を短縮し、コストを削減し、専門知識を利用することを可能にし、コンセプトから臨床評価まで、医薬品候補の効率的かつコンプライアンスに則った進行を保証します。

予測期間中にCAGRが最も高くなると予想されるのはバイオテクノロジー企業セグメントです。

バイオテクノロジー企業セグメントは、予測期間中に最も高いCAGR成長が見込まれます。CDMOはバイオテクノロジー企業に医薬品開発・製造のための専門サービスを記載しています。CDMOは、製剤化、臨床試験支援、大規模製造などのセグメントで専門知識を記載しています。これらの業務をアウトソーシングすることで、バイオテクノロジー企業はイノベーションに集中し、CDMOの高度な技術や規制遵守の専門知識から恩恵を受けながら、新治療法の市場投入までの時間を短縮することができます。

最大のシェアを占める地域

予測期間中、アジア太平洋が最大の市場シェアを占めると予測されています。製薬・バイオテクノロジー産業の急拡大、コスト効率の高いソリューションを求める欧米企業のアウトソーシング動向の増加、熟練労働者が低コストで入手可能であることなどが主要促進要因となっています。さらに、ライフサイエンスセグメントを促進するための好ましい規制環境と政府の取り組みが、市場の成長をさらに後押ししています。ジェネリック医薬品や生物製剤の需要が急増しているアジア太平洋は、幅広い開発・製造サービスを提供するCDMOの戦略的拠点になりつつあります。

CAGRが最も高い地域：

予測期間中、北米のCAGRが最も高いと予測されます。技術革新、品質、効率に重点を置く北米のCDMOは、医薬品開発、製造、包装、サプライチェーン管理にわたるエンドツーエンドのソリューションを提供しています。この地域は、強力な規制の枠組み、熟練した労働力、高度なインフラから利益を得ており、国内外の顧客を惹きつけています。主要企業は、進化する業界の需要に対応するため、常に研究開発と技術進歩に投資し、市場での競合と持続可能性を確保しています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携別の主要企業のベンチマーキング

目次

第1章 エグゼクティブ概要

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の医薬品開発・製造受託機関市場：サービスタイプ別

• イントロダクション
• 開発サービス
  • プレフォーミュレーションサービス
  • 処方開発
  • プロセス開発
  • 分析と品質管理サービス
• 製造サービス
  • 医薬品有効成分（API）製造
  • 完成剤形の製造
  • 包装
  • 商業製造
• 臨床試験材料（CTM）製造
• スケールアップサービス
• 規制サポートサービス
• その他

第6章 世界の医薬品開発・製造受託機関市場：分子タイプ別

• イントロダクション
• 低分子医薬品
• 生物製剤
  • モノクローナル抗体
  • ワクチン
  • 組み換えタンパク質
• その他

第7章 世界の医薬品開発・製造受託機関市場：剤形別

• イントロダクション
• 固体
• 液体
• 注射
• 吸入薬
• その他

第8章 世界の医薬品開発・製造受託機関市場：用途別

• イントロダクション
• 腫瘍学
• 心血管疾患
• 中枢神経系（CNS）障害
• 感染症
• 代謝障害
• 呼吸器疾患
• その他

第9章 世界の医薬品開発・製造受託機関市場：エンドユーザー別

• イントロダクション
• 製薬会社
• バイオテクノロジー企業
• ジェネリック医薬品会社
• その他

第10章 世界の医薬品開発・製造受託機関市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第11章 主要開発

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第12章 企業プロファイリング

• Lonza Group
• Catalent Inc.
• WuXi AppTec
• Samsung Biologics
• Boehringer Ingelheim BioXcellence
• Parexel International
• Thermo Fisher Scientific
• Siegfried Holding AG
• Fujifilm Diosynth Biotechnologies
• Recipharm AB
• Albany Molecular Research Inc.（AMRI）
• Piramal Pharma Solutions
• Charles River Laboratories
• Ajinomoto Bio-Pharma Services
• Alcami Corporation
• Cambrex Corporation
• Hovione
• Fareva
• Sartorius Stedim BioOutsource
• Micron Technologies

List of Tables

• Table 1 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Region (2022-2030) ($MN)
• Table 2 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Service Type (2022-2030) ($MN)
• Table 3 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Development Services (2022-2030) ($MN)
• Table 4 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Preformulation Services (2022-2030) ($MN)
• Table 5 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Formulation Development (2022-2030) ($MN)
• Table 6 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Process Development (2022-2030) ($MN)
• Table 7 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Analytical & Quality Control Services (2022-2030) ($MN)
• Table 8 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Manufacturing Services (2022-2030) ($MN)
• Table 9 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Active Pharmaceutical Ingredients (API) Manufacturing (2022-2030) ($MN)
• Table 10 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Finished Dosage Form Manufacturing (2022-2030) ($MN)
• Table 11 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Packaging (2022-2030) ($MN)
• Table 12 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Commercial Manufacturing (2022-2030) ($MN)
• Table 13 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Clinical Trial Material (CTM) Production (2022-2030) ($MN)
• Table 14 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Scale-Up Services (2022-2030) ($MN)
• Table 15 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Regulatory Support Services (2022-2030) ($MN)
• Table 16 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Other Service Types (2022-2030) ($MN)
• Table 17 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Molecule Type (2022-2030) ($MN)
• Table 18 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Small Molecule Drugs (2022-2030) ($MN)
• Table 19 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Biologics (2022-2030) ($MN)
• Table 20 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
• Table 21 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Vaccines (2022-2030) ($MN)
• Table 22 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Recombinant Proteins (2022-2030) ($MN)
• Table 23 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Other Molecule Types (2022-2030) ($MN)
• Table 24 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Dosage Form (2022-2030) ($MN)
• Table 25 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Solid (2022-2030) ($MN)
• Table 26 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Liquid (2022-2030) ($MN)
• Table 27 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Injectable (2022-2030) ($MN)
• Table 28 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Inhalables (2022-2030) ($MN)
• Table 29 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Other Dosage Forms (2022-2030) ($MN)
• Table 30 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Application (2022-2030) ($MN)
• Table 31 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Oncology (2022-2030) ($MN)
• Table 32 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Cardiovascular Diseases (2022-2030) ($MN)
• Table 33 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Central Nervous System (CNS) Disorders (2022-2030) ($MN)
• Table 34 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Infectious Diseases (2022-2030) ($MN)
• Table 35 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
• Table 36 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Respiratory Diseases (2022-2030) ($MN)
• Table 37 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Other Applications (2022-2030) ($MN)
• Table 38 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By End User (2022-2030) ($MN)
• Table 39 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Pharmaceutical Companies (2022-2030) ($MN)
• Table 40 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Biotechnology Companies (2022-2030) ($MN)
• Table 41 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Generic Drug Companies (2022-2030) ($MN)
• Table 42 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market is accounted for $243.29 billion in 2024 and is expected to reach $354.68 billion by 2030 growing at a CAGR of 8.4% during the forecast period. A Pharmaceutical Contract Development & Manufacturing Organization (CDMO) is a specialized corporation that provides comprehensive services to pharmaceutical and biotechnology companies. These services encompass the entire drug development and manufacturing process, from initial product concept to commercial production. CDMOs offer expertise in formulation development, analytical testing, process optimization, and regulatory compliance. They enable clients to outsource various aspects of drug development and production, allowing them to focus on core competencies while benefiting from the CDMO's specialized capabilities and infrastructure.

According to the National Health Commission (NHC), China has over 180 million elderly citizens suffering from chronic diseases, of which 75% have more than one.

Market Dynamics:

Driver:

Rising biopharmaceuticals market

The rising biopharmaceuticals market fuels demand for specialized expertise and infrastructure, driving the expansion of PCDMOs. These organizations offer tailored solutions for drug development, manufacturing, and testing, catering to the unique requirements of biopharmaceuticals. CDMOs streamline processes, reduce costs, and mitigate risks for pharmaceutical companies, fostering innovation and accelerating time-to-market for new therapies. As biopharmaceuticals continue to dominate the market, CDMOs play a pivotal role in supporting their development and commercialization efforts, fueling the growth trajectory of the sector.

Restraint:

Stringent regulatory requirements & compliance standards

Stringent regulatory requirements and compliance standards in CDMOs are essential to ensure product quality, safety, and efficacy. These standards can hamper market growth by increasing operational costs, lengthening development timelines, and creating barriers to entry for smaller companies. Compliance efforts often require substantial resources, leading to higher prices for services and products. Additionally, stringent regulations may deter innovation and limit flexibility in adapting to market demands, thus impeding overall market expansion and competitiveness.

Opportunity:

Growing demand for specialized expertise

As pharmaceutical companies seek to focus on core competencies while leveraging external expertise, CDMOs play a crucial role in providing specialized services such as formulation development, manufacturing, and packaging. This trend is fuelled by the complexities of modern drug development, stringent regulatory requirements, and the need for cost-effective strategies. CDMOs provide a range of services including formulation development, analytical testing, manufacturing, and packaging, allowing pharmaceutical companies to accelerate their product pipelines and bring innovative treatments to market efficiently, thereby propelling market expansion.

Threat:

Pricing pressures

Pricing pressures in CDMOs arise due to increased competition, regulatory changes, and rising costs of raw materials and labor. These pressures often lead to downward pricing trends, squeezing profit margins and hindering investment in innovation and expansion. Consequently, CDMOs may struggle to maintain profitability and may be unable to invest in advanced technologies or infrastructure upgrades. This cycle of constrained investment can impede the development of new drugs and limit the industry's ability to meet evolving healthcare needs.

Covid-19 Impact

The covid-19 pandemic has had mixed impacts on the pharmaceutical contract development & manufacturing organization (CDMO) market. While the demand for certain pharmaceutical products, such as vaccines and treatments, surged, leading to increased outsourcing to CDMOs for manufacturing support, the pandemic also disrupted supply chains and delayed clinical trials and regulatory processes. Overall, the pandemic emphasized the importance of agile and resilient manufacturing capabilities, driving investment in technology and infrastructure to mitigate future disruptions.

The development services segment is expected to be the largest during the forecast period

The development services segment is estimated to have a lucrative growth. A pharmaceutical contract development & manufacturing organization in development services provides comprehensive support from drug discovery to clinical trials. These services include formulation development, analytical method development, stability studies, and regulatory submissions. CDMOs enable pharmaceutical companies to accelerate development timelines, reduce costs, and access specialized expertise, ensuring efficient and compliant progression of drug candidates from concept to clinical evaluation.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

The biotechnology companies segment is anticipated to witness the highest CAGR growth during the forecast period. CDMOs provide biotechnology companies with specialized services for drug development and production. They offer expertise in areas like formulation, clinical trial support, and large-scale manufacturing. By outsourcing these tasks, biotech firms can focus on innovation and reduce time-to-market for new therapies, benefiting from CDMOs' advanced technologies and regulatory compliance expertise.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Rapidly expanding pharmaceutical and biotechnology industries, increasing outsourcing trends from Western companies seeking cost-effective solutions, and the availability of skilled labor at lower costs are key drivers. Additionally, favourable regulatory environments and government initiatives to promote the life sciences sector further boost market growth. With a burgeoning demand for generic drugs and biologics, the Asia Pacific region is becoming a strategic hub for CDMOs offering a wide range of development and manufacturing services.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. With a focus on innovation, quality, and efficiency, North American CDMOs offer end-to-end solutions spanning drug development, manufacturing, packaging, and supply chain management. The region benefits from a strong regulatory framework, skilled workforce, and advanced infrastructure, attracting both domestic and international clients. Key players constantly invest in R&D and technological advancements to meet evolving industry demands, ensuring competitiveness and sustainability in the market.

Key players in the market

Some of the key players profiled in the Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market include Lonza Group, Catalent Inc., WuXi AppTec, Samsung Biologics, Boehringer Ingelheim BioXcellence, Parexel International, Thermo Fisher Scientific, Siegfried Holding AG, Fujifilm Diosynth Biotechnologies, Recipharm AB, Albany Molecular Research Inc. (AMRI), Piramal Pharma Solutions, Charles River Laboratories, Ajinomoto Bio-Pharma Services, Alcami Corporation, Cambrex Corporation, Hovione, Fareva, Sartorius Stedim BioOutsource, Micron Technologies.

Key Developments:

In June 2023, FUJIFILM Corporation launched a commercial office in Tokyo to provide enhanced sales support and customer service for Contract Development and Manufacturing services for Biologics and Advanced Therapies to Asia-based pharmaceutical and biotechnology companies.

In April 2023, Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, has an agreement with ABL Bio, a pioneering Korean biologics company with a focus on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration agreement between Lonza and ABL Bio supports the development and manufacturing of ABL Bio's new bispecific antibody product.

Service Types Covered:

• Development Services
• Manufacturing Services
• Clinical Trial Material (CTM) Production
• Scale-Up Services
• Regulatory Support Services
• Other Service Types

Molecule Types Covered:

• Small Molecule Drugs
• Biologics
• Other Molecule Types

Dosage Forms Covered:

• Solid
• Liquid
• Injectable
• Inhalables
• Other Dosage Forms

Applications Covered:

• Oncology
• Cardiovascular Diseases
• Central Nervous System (CNS) Disorders
• Infectious Diseases
• Metabolic Disorders
• Respiratory Diseases
• Other Applications

End Users Covered:

• Pharmaceutical Companies
• Biotechnology Companies
• Generic Drug Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Service Type

• 5.1 Introduction
• 5.2 Development Services
  • 5.2.1 Preformulation Services
  • 5.2.2 Formulation Development
  • 5.2.3 Process Development
  • 5.2.4 Analytical & Quality Control Services
• 5.3 Manufacturing Services
  • 5.3.1 Active Pharmaceutical Ingredients (API) Manufacturing
  • 5.3.2 Finished Dosage Form Manufacturing
  • 5.3.3 Packaging
  • 5.3.4 Commercial Manufacturing
• 5.4 Clinical Trial Material (CTM) Production
• 5.5 Scale-Up Services
• 5.6 Regulatory Support Services
• 5.7 Other Service Types

6 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Molecule Type

• 6.1 Introduction
• 6.2 Small Molecule Drugs
• 6.3 Biologics
  • 6.3.1 Monoclonal Antibodies
  • 6.3.2 Vaccines
  • 6.3.3 Recombinant Proteins
• 6.4 Other Molecule Types

7 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Dosage Form

• 7.1 Introduction
• 7.2 Solid
• 7.3 Liquid
• 7.4 Injectable
• 7.5 Inhalables
• 7.6 Other Dosage Forms

8 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Application

• 8.1 Introduction
• 8.2 Oncology
• 8.3 Cardiovascular Diseases
• 8.4 Central Nervous System (CNS) Disorders
• 8.5 Infectious Diseases
• 8.6 Metabolic Disorders
• 8.7 Respiratory Diseases
• 8.8 Other Applications

9 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical Companies
• 9.3 Biotechnology Companies
• 9.4 Generic Drug Companies
• 9.5 Other End Users

10 Global Pharmaceutical Contract Development & Manufacturing Organization (CDMO) Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Lonza Group
• 12.2 Catalent Inc.
• 12.3 WuXi AppTec
• 12.4 Samsung Biologics
• 12.5 Boehringer Ingelheim BioXcellence
• 12.6 Parexel International
• 12.7 Thermo Fisher Scientific
• 12.8 Siegfried Holding AG
• 12.9 Fujifilm Diosynth Biotechnologies
• 12.10 Recipharm AB
• 12.11 Albany Molecular Research Inc. (AMRI)
• 12.12 Piramal Pharma Solutions
• 12.13 Charles River Laboratories
• 12.14 Ajinomoto Bio-Pharma Services
• 12.15 Alcami Corporation
• 12.16 Cambrex Corporation
• 12.17 Hovione
• 12.18 Fareva
• 12.19 Sartorius Stedim BioOutsource
• 12.20 Micron Technologies